Quarterly ResultMay 15, 2026, 07:12 AM
BioXcel Therapeutics Q1 Net Loss Widens to $12.7M; Going Concern Doubt
AI Summary
BioXcel Therapeutics reported a net loss of $12.7 million for Q1 2026, a significant increase from $7.3 million in Q1 2025. The company's cash and cash equivalents decreased to $17.2 million from $28.4 million at year-end 2025. Management has identified substantial doubt about the company's ability to continue as a going concern due to significant losses, negative cash flows, and current debt obligations, despite ongoing efforts to raise additional capital and reduce expenses.
Key Highlights
- Substantial doubt about BioXcel Therapeutics' ability to continue as a going concern.
- Net loss widened to $12.7 million in Q1 2026 from $7.3 million in Q1 2025.
- Product revenue, net, increased to $206 thousand in Q1 2026 from $168 thousand in Q1 2025.
- Cash and cash equivalents decreased to $17.2 million as of March 31, 2026.
- Net cash used in operating activities was $11.8 million in Q1 2026.
- Total stockholders' deficit increased to $105.5 million as of March 31, 2026.
- Total debt liability was $104.0 million as of March 31, 2026.
Price Impact
More from BTAI